Skip to content

Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer in Combination with Fulvestrant as Initial Endocrine-based Therapy in Women

Products containing Ribociclib feature in this group.

Kisqali

Ribociclib

200mg

Treats hormone receptor-positive, HER2-negative breast cancer by inhibiting cyclin-dependent kinases 4 and 6, thereby halting cancer cell division and slowing tumour growth.

From$93.60/ tabletView

Review product labelling and speak with a healthcare professional before treatment decisions.